Glycosylation is one of the most important post-translational modifications of eukaryotic proteins. Differences in glycosylation can affect protein structure, stability, immunogenicity, and function. Thus, glycomics plays a significant part in health and disease. In addition, biotherapeutics, including monoclonal antibodies (mAbs), are often glycosylated, and the extent, type, and location of the glycan structures present on the proteins impact the mechanism of action, pharmacokinetics, and efficacy of these drugs. In some cases, when non-human glycan structures are present, they can trigger an undesirable immune response. Glycan analysis, as a result, is critical for determining the quality of biotherapeutics.
Until recently, analytical methods have been slow and tedious and largely limited to use in the later stages of product development. The introduction of high-throughput techniques is, however, creating opportunities for the application of glycan analysis early in bioprocess development.
We offer a high throughput kits & glycan profiling services to analyse N-glycan & O-Glycan in biological samples including biotherapeutics glycoproteins & vaccines in a simple, safe & streamlined operations.